Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02586727
Other study ID # LCH-1-012015
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 2015
Est. completion date August 2020

Study information

Verified date October 2023
Source Larkin Community Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the study is to assess the safety of intravitreal aflibercept injection in treating visually compromising radiation maculopathy secondary to treatment of uveal melanoma by iodione-125 brachytherapy. The study will consist of two arms of 25 patients each (totaling 50 patients). Subjects in arm 1 will undergo treatment every 6 weeks. Subjects in arm 2 will undergo treatment and if improvement is documented at the following evaluation the next treatment will be extended by two weeks. Secondary objectives of the study include evaluation and analysis of visual acuity, number of injections, macular edema, and vascular activity between both arms.


Description:

This study will consist of 2 simultaneous treatment arms: A six week dosing regimen arm and a treat and extend (TAE) dosing regimen arm, total duration 54 weeks. In the TAE arm the patients will receive an intravitreal aflibercept injection first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward. Treatment will be given at each visit. Patients with improved radiation maculopathy (SD-OCT analysis) will extend re-evaluation by two weeks (e.g. first interval 6 weeks; second interval 10 weeks; third interval 12 weeks, etc). Patients with increased radiation maculopathy (SD-OCT analysis) will have re-evaluation decreased by one week. Both arms will consist of 25 subjects (eyes). Fluorescein angiography will be completed at baseline, after the 4th injection (or within three weeks of week 24 for the TAE arm), and at the end of the study in all patients. Spectral domain OCT, and clinical evaluation including visual acuity will be assessed every visit in all patients. Radiation maculopathy will be graded every visit in all patients in a blinded fashion using the following classification system: Grade 1 indicates extrafoveal, noncystoid edema; grade 2, extrafoveal cystoid edema; grade 3, foveal noncystoid edema; grade 4, mild-to-moderate foveal cystoid edema; grade 5, severe foveal cystoid edema and grade 6 subretinal fluid. All patients will undergo comprehensive evaluation including adverse event questioning at each study timepoint. Patients in the six-week dosing arm will receive a total of 9 intravitreal aflibercept injections during the study window while the TAE treatment group will receive a maximum of 9 with a minimum of 5.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date August 2020
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - A Patient must meet the following criteria to be eligible for inclusion in the study: 1. 21 years of age and over 2. 20/800 or better visual acuity 3. Must have received previous treatment for radiation maculopathy within the last 4-26 weeks 4. Any presence of macular edema (evaluated by SD-OCT) caused by radiation retinopathy 5. Willing and able to comply with clinic visits and study-related procedures 6. Provide signed informed consent Exclusion Criteria: - A patient who meets any of the following criteria will be excluded from the study: 1. Patients less than 21 years of age. 2. Patients with mental disability or any other condition that precludes the acquisition of an sdOCT image such as (nystagmus, neck disease, etc.) 3. Patients who have previously been treated with intravitreal triamcinolone acetonide for macular edema (signs of recalcitrant disease)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
aflibercept
This study will consist of 2 simultaneous treatment arms of aflibercept: A six week dosing regimen arm and a treat and extend (TAE) dosing regimen arm, total duration 54 weeks. In the TAE arm the patients will receive an intravitreal aflibercept injection first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Larkin Community Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Best Corrected Visual Acuity (BCVA) in Patients Treated With Intravitreal Aflibercept Injections for the Management of Radiation Maculopathy. BCVA will be measured with letter optotypes. A lower value indicates a better outcome. 12 months
Secondary Role of Intravitreal Aflibercept Injection on Central Retinal Thickness for the Treatment of Radiation Maculopathy. Central retinal thickness will be evaluated with OCT. A lower value considered a better outcome. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT02052102 - Study to See Whether Breath-Hold Techniques During RT Are Effective in Helping to Improve Sparing of the Heart Phase 2
Unknown status NCT01863420 - The Effect of Bone Marrow-sparing Intensity-Modulated Radiotherapy to GI Cancer Phase 2
Completed NCT02922244 - Effects of Herbal Products on Reduction of Radiation-induced Dermatitis in Breast Cancer Patients N/A
Completed NCT02406183 - Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma Phase 1
Completed NCT01621880 - Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma Phase 2
Enrolling by invitation NCT02066974 - Circulating Tumor Cell Genome in Peripheral Blood From Hepatocellular Carcinoma Patients Under Radiotherapy N/A
Active, not recruiting NCT02114086 - IORT-Boost-Study, Prospective Observational Study for Intraoperative Radiotherapy of the Breast as a Boost
Completed NCT02142907 - Evaluation of Two Boost Radiation Schedules in Post Lumpectomy Early Stage Carcinoma Breast
Not yet recruiting NCT04127760 - Efficacy of Postoperative Radiotherapy for Atypical Meningioma Without Venous Sinus Invasion After Gross-total Resection N/A
Recruiting NCT04553510 - Treatment of Bevacizumab Followed by Steroid in RN Phase 2
Completed NCT03359187 - Prevention of Mucositis in Patients With Head and Neck Cancer Treated With Radiotherapy N/A
Completed NCT00780312 - Physiotherapy Treatment for Patients Suffering From Head and Neck Cancer Phase 2